rates and inhibitors of the drug transporter P-glycoprotein (P-gp). In addition, diltiazem is an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Dronedarone: Use caution when administering velpatasvir with dronedarone. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); dronedarone is an inhibitor of P-gp. Dronedarone is also an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Drospirenone; Ethinyl Estradiol: Use caution when administering velpatasvir with ethinyl estradiol. Taking these drugs together may increase the plasma concentrations velpatasvir and ethinyl estradiol, potentially resulting in adverse events. Velpatasvir is a CYP2B6 and CYP3A4 substrate; ethinyl estradiol is an in vitro inhibitor of CYP2B6 and CYP3A4. In addition, ethinyl estradiol is a substrate for the drug transporter P-glycoprotein (P-gp); velpatasvir is a P-gp inhibitor.
Drospirenone; Ethinyl Estradiol; Levomefolate: Use caution when administering velpatasvir with ethinyl estradiol. Taking these drugs together may increase the plasma concentrations velpatasvir and ethinyl estradiol, potentially resulting in adverse events. Velpatasvir is a CYP2B6 and CYP3A4 substrate; ethinyl estradiol is an in vitro inhibitor of CYP2B6 and CYP3A4. In addition, ethinyl estradiol is a substrate for the drug transporter P-glycoprotein (P-gp); velpatasvir is a P-gp inhibitor.
Efavirenz: Avoid coadministration of velpatasvir with inducers of CYP3A4 and CYP2B6, such as efavirenz. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 and CYP2B6 substrate.
Efavirenz; Emtricitabine; Tenofovir: Avoid coadministration of velpatasvir with inducers of CYP3A4 and CYP2B6, such as efavirenz. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 and CYP2B6 substrate. Monitor patients for tenofovir-associated adverse reactions, such as renal toxicity, in patients receiving regimens containing tenofovir and velpatasvir due to potential increases in tenofovir serum concentrations. Tenofovir is a substrate of the breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) transporters, while velpatasvir inhibits both BCRP and P-gp.
Elbasvir; Grazoprevir: Use caution when administering velpatasvir with grazoprevir. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Velpatasvir is a substrate for the Breast Cancer Resistance Protein (BCRP). Grazoprevir is a BCRP inhibitor. Grazoprevir is also a weak CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4. Additionally, velpatasvir is an inhibitor of the organic anion transporting polypeptides OATP1B1 and OATP1B3. grazoprevir is an OATP1B1/3 substrate.
Eliglustat: Use caution when administering velpatasvir with eliglustat. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); eliglustat is an inhibitor of P-gp.
Eluxadoline: Use caution when administ |
